Cryptotanshinone alleviates vasculitis in Kawasaki disease by modulating macrophage-neutrophil interactions

Abstract

Kawasaki disease (KD) is a form of vasculitis that affects primarily children and can lead to severe cardiovascular complications. Because current treatment options are often ineffective for some patients, new therapeutic strategies are needed. Cryptotanshinone (CTS), a compound derived from Salvia miltiorrhiza Bunge, has shown potential as an anti-inflammatory agent. Herein, in a mouse model of KD induced by Lactobacillus casei cell wall extract (LCWE), CTS was found to significantly decrease inflammation in the aortic root and coronary arteries. This treatment inhibited the activation of macrophages and neutrophils, which are critical contributors to KD. Network pharmacology analysis suggested that CTS modulates the chemokine signaling pathway, thereby inhibiting the recruitment of inflammatory cells and preventing further vasculitis progression. Single-nucleus RNA sequencing (snRNA-seq) revealed that CTS decreased macrophage numbers and chemokine activity, particularly that of Ccl8, and consequently neutrophil recruitment. Our findings suggest that CTS might provide a promising therapeutic option for KD by modulating immune cell interactions and inflammation.

Keywords

Kawasaki Disease / Vasculitis / Cryptotanshinone / Macrophages / Chemotaxis

References

[1] Newburger JW, Takahashi M, Burns JC: Kawasaki Disease. Journal of the American College of Cardiology 2016, 67: 1738-1749.

[2] McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al.: Diagnosis, Treatment, and Long-term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017, 135: e927-e999.

[3] Burns JC, Glodé MP: Kawasaki Syndrome. The Lancet (London, England) 2004, 364: 533-544.

[4] Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al.: Randomized Trial of Pulsed Corticosteroid Therapy for Primary Treatment of Kawasaki Disease. The New England Journal of Medicine 2007, 356: 663-675.

[5] James KE, Kalot MA, Husainat NM, Dua AB, Byram K, Springer JM, et al.: Kawasaki Disease: A Systematic Review and Meta-analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatology 2021, 3: 671-683.

[6] Sharma S, Goel S, Goyal T, Pilania RK, Aggarwal R, Kaur T, et al.: Single-cell RNA Sequencing: An Emerging Tool Revealing Dysregulated Innate and Adaptive Immune Response at Single Cell Level in Kawasaki Disease. Expert Review of Clinical Immunology 2025, 21: 83-92.

[7] Lo MS: A Framework for Understanding Kawasaki Disease Pathogenesis. Clinical Immunology 2020, 214: 108385.

[8] Nadig PL, Joshi V, Pilania RK, Kumrah R, Kabeerdoss J, Sharma S, et al.: Intravenous Immunoglobulin in Kawasaki Disease-evolution and Pathogenic Mechanisms. Diagnostics (Basel) 2023, 13: 2338.

[9] Noval Rivas M, Arditi M: Kawasaki Disease: Pathophysiology and Insights from Mouse Models. Nature Reviews. Rheumatology 2020, 16: 391-405.

[10] Menikou S, Langford PR, Levin M: Kawasaki Disease: The Role of Immune Complexes Revisited. Frontiers in Immunology 2019, 10: 1156.

[11] Tang B, Lo HH, Lei C, In U Ka, Hsiao WW, Guo X, et al.: Adjuvant Herbal Therapy for Targeting Susceptibility Genes to Kawasaki Disease: An Overview of Epidemiology, Pathogenesis, Diagnosis and Pharmacological Treatment of Kawasaki Disease. Phytomedicine 2020, 70: 153208.

[12] Yan ZT, Zou JW: Triptolide as an Alternative to IVIG Therapy for Kawasaki Disease in a Mouse Model. Balkan Medical Journal 2013, 30: 225-228.

[13] Domiciano TP, Wakita D, Jones HD, Crother TR, Verri WA Jr, Arditi M, et al.: Quercetin Inhibits Inflammasome Activation by Interfering with ASC Oligomerization and Prevents Interleukin-1 Mediated Mouse Vasculitis. Scientific Reports 2017, 7: 41539.

[14] Zhang Q, Gan C, Liu H, Wang L, Li Y, Tan Z, et al.: Cryptotanshinone Reverses the Epithelial-mesenchymal Transformation Process and Attenuates Bleomycin-induced Pulmonary Fibrosis. Phytotherapy Research 2020, 34: 2685-2696.

[15] Li ZM, Xu SW, Liu PQ: Salvia MiltiorrhizaBurge (Danshen): A Golden Herbal Medicine in Cardiovascular Therapeutics. Acta Pharmacologica Sinica 2018, 39: 802-824.

[16] Min X, Zeng X, Zhao W, Han Z, Wang Y, Han Y, et al.: Cryptotanshinone Protects Dextran Sulfate Sodium-induced Experimental Ulcerative Colitis in Mice by Inhibiting Intestinal Inflammation. Phytotherapy Research 2020, 34: 2639-2648.

[17] Wang N, Dong X, Shi D, Li N, Zhang Q: Cryptotanshinone Ameliorates Placental Oxidative Stress and Inflammation in Mice with Gestational Diabetes Mellitus. Archives of Pharmacal Research 2020, 43: 755-764.

[18] Ahmad Z, Ng CT, Fong LY, Bakar NAA, Hussain NHM, Ang KP, et al.: Cryptotanshinone Inhibits TNF-α-induced Early Atherogenic Events In Vitro. The Journal of Physiological Sciences 2016, 66: 213-220.

[19] Zhang X, Bian Z, Zhang J, Ding L, Cao G, Zhu L, et al.: Research Progress on the Mechanism of Anti-myocardial Infarction Effect and Clinical Application of Effective Components of Salvia Miltiorrhiza. Medicinal Chemistry Research 2024, 33: 239-253.

[20] Hopkins AL: Network Pharmacology: The Next Paradigm in Drug Discovery. Nature Chemical Biology 2008, 4: 682-690.

[21] Zeng L, Yang K, Zhang T, Zhu X, Hao W, Chen H, et al.: Research Progress of Single-cell Transcriptome Sequencing in Autoimmune Diseases and Autoinflammatory Disease: A Review. Journal of Autoimmunity 2022, 133: 102919.

[22] Noval Rivas M, Wakita D, Franklin MK, Carvalho TT, Abolhesn A, Gomez AC, et al.: Intestinal Permeability and IgA Provoke Immune Vasculitis Linked to Cardiovascular Inflammation. Immunity 2019, 51: 508-521.e6.

[23] Porritt RA, Zemmour D, Abe M, Lee Y, Narayanan M, Carvalho TT, et al.: NLRP3 Inflammasome Mediates Immune-Stromal Interactions in Vasculitis. Circulation Research 2021, 129: e183-e200.

[24] Li S, Yang Z: Plasma Cyclooxygenase-2 as a Potential Biomarker for Early Diagnosis of Kawasaki Disease. Fetal and Pediatric Pathology 2023, 42: 569-580.

[25] Guo M, Fan S, Chen Q, Jia C, Qiu M, Bu Y, et al.: Platelet-derived microRNA-223 Attenuates TNF-α Induced Monocytes Adhesion to Arterial Endothelium by Targeting ICAM-1 in Kawasaki Disease. Frontiers in Immunology 2022, 13: 922868.

[26] Campbell NK, Fitzgerald HK, Dunne A: Regulation of Inflammation by the Antioxidant Haem Oxygenase 1. Nature Reviews. Immunology 2021, 21: 411-425.

[27] Chen Y, Yang M, Zhang M, Wang H, Zheng Y, Sun R, et al.: Single-cell Transcriptome Reveals Potential Mechanisms for Coronary Artery Lesions in Kawasaki Disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2024, 44: 866-882.

[28] Sharma C, Ganigara M, Galeotti C, Burns J, Berganza FM, Hayes DA, et al.: Multisystem Inflammatory Syndrome in Children and Kawasaki Disease: A Critical Comparison. Nature Reviews Rheumatology 2021, 17: 731-748.

[29] Sato W, Yokouchi Y, Oharaseki T, Asakawa N, Takahashi K: The pathology of Kawasaki Disease Aortitis: A Study of 37 Cases. Cardiovascular Pathology 2021, 51: 107303.

[30] Tan J, Liang Y, Yang Z, He Q, Tong J, Deng Y, et al.: Single-cell Transcriptomics Reveals Crucial Cell Subsets and Functional Heterogeneity Associated With Carotid Atherosclerosis and Cerebrovascular Events. Arteriosclerosis, Thrombosis, and Vascular Biology 2023, 43: 2312-2332.

[31] Stock AT, Hansen JA, Sleeman MA, McKenzie BS, Wicks IP: GM-CSF Primes Cardiac Inflammation in a Mouse Model of Kawasaki Disease. The Journal of Experimental Medicine 2016, 213: 1983-1998.

[32] Puertollano R, Ferguson SM, Brugarolas J, Ballabio A: The Complex Relationship Between TFEB Transcription Factor Phosphorylation and Subcellular Localization. The EMBO Journal 2018, 37: e98804.

[33] Tan A, Prasad R, Lee C, Jho EH: Past, Present, and Future Perspectives of Transcription Factor EB (TFEB): Mechanisms of Regulation and Association with Disease. Cell Death and Differentiation 2022, 29: 1433-1449.

[34] Slade L, Pulinilkunnil T: The MiTF/TFE Family of Transcription Factors: Master Regulators of Organelle Signaling, Metabolism, and Stress Adaptation. Molecular Cancer Research 2017, 15: 1637-1643.

[35] Agostini F, Agostinis R, Medina DL, Bisaglia M, Greggio E, Plotegher N: The Regulation of MiTF/TFE Transcription Factors Across Model Organisms: From Brain Physiology to Implication for Neurodegeneration. Molecular Neurobiology 2022, 59: 5000-5023.

[36] Sun HM, Chen XL, Chen XJ, Liu J, Ma L, Wu HY, et al.: PALLD Regulates Phagocytosis by Enabling Timely Actin Polymerization and Depolymerization. Journal of Immunology (Baltimore, Md.: 1950) 2017, 199: 1817-1826.

[37] Hara T, Yamamura K, Sakai Y: The Up-to-Date Pathophysiology of Kawasaki Disease. Clinical & Translational Immunology 2021, 10: e1284.

[38] Mahmoudinezhad Dezfouli SM, Salehi S, Khosravi S: Pathogenic and Therapeutic Roles of Cytokines in Kawasaki Diseases. Clinica Chimica Acta 2022, 532: 21-28.

[39] Rife E, Gedalia A: Kawasaki Disease: An Update. Current Rheumatology Reports 2020, 22: 75.

[40] Wang Y, Li T: Advances in Understanding Kawasaki Disease-related Immuno-inflammatory Response and Vascular Endothelial Dysfunction. Pediatric Investigation 2022, 6: 271-279.

[41] Xie Z, Huang Y, Li X, Lun Y, Li X, He Y, et al.: Atlas of Circulating Immune Cells in Kawasaki Disease. International Immunopharmacology 2022, 102: 108396.

[42] Rodríguez-Morales P, Franklin RA: Macrophage Phenotypes and Functions: Resolving Inflammation and Restoring Homeostasis. Trends in Immunology 2023, 44: 986-998.

[43] Liu C, Wu C, Yang Q, Gao J, Li L, Yang D, et al.: Macrophages Mediate the Repair of Brain Vascular Rupture through Direct Physical Adhesion and Mechanical Traction. Immunity 2016, 44: 1162-1176.

[44] Gao Z, Du Z, Hou Y, Hua K, Tu P, Ai X, et al.: A microfluidic Coculture Model for Mapping Signaling Perturbations and Precise Drug Screening Against Macrophage-mediated Dynamic Myocardial Injury. Acta Pharmaceutica Sinica. B 2024, 14: 5393-5406.

[45] Miyabe C, Miyabe Y, Bricio-Moreno L, Lian J, Rahimi RA, Miura NN, et al.: Dectin-2-induced CCL2 Production in Tissue-resident Macrophages Ignites Cardiac Arteritis. The Journal of Clinical Investigation 2019, 129: 3610-3624.

[46] Chen R, Zhang H, Tang B, Luo Y, Yang Y, Zhong X, et al.: Macrophages in Cardiovascular Diseases: Molecular Mechanisms and Therapeutic Targets. Signal Transduction and Targeted Therapy 2024, 9: 130.

[47] Honold L, Nahrendorf M: Resident and Monocyte-Derived Macrophages in Cardiovascular Disease. Circulation Research 2018, 122: 113-127.

[48] Ye Z, Wang P, Feng G, Wang Q, Liu C, Lu J, et al.: Cryptotanshinone Attenuates LPS-induced Acute Lung Injury by Regulating Metabolic Reprogramming of Macrophage. Frontiers in Medicine (Lausanne) 2022, 9: 1075465.